(Press-News.org) Patients prescribed drugs to help them lose weight may experience a rebound in weight gain after halting their prescription, finds a meta-analysis published in BMC Medicine. The study, which analyses data for patients receiving weight loss drugs across 11 randomised trials, suggests that while the amount of weight regain varies depending on the specific drug, there is a broad trend in associated weight regain after the course of medication concluded.
Six anti-obesity medications (AOMs) have been approved by the US FDA for use in assisting with weight loss, including orlistat, phentermine-topiramate, and semaglutide. Glucagon-like peptide-1 (GLP-1) — a therapeutic developed to assist with diabetes — has also increasingly been prescribed to help patients lose weight. However, recent studies have suggested that patients prescribed AOMs may regain weight in the months after stopping taking these medications.
Xiaoling Cai, Linong Ji, and colleagues conducted a meta-analysis of 11 studies from around the world investigating weight change in patients after they stopped taking AOMs. Overall, the authors analysed data from 1,574 participants in treatment groups and 893 in control groups. Weight change was measured by changes in body weight and BMI after stopping medication. Of the 11 studies included in the meta-analysis: six focused on GLP-1 receptor agonists (RAs); one focused on GLP-1 and GLP dual Ras; one study focused on orlistat; two studies on phentermine-topiramate; and one study on naltexone-bupriopion.
The authors controlled for different contributing factors, including medication type, the presence of diabetes, and the presence or absence of lifestyle changes like diet or exercise. Their analysis found that AOMs were associated with significant weight loss while being used, followed by weight regain starting eight weeks after AOM discontinuation, with weight regain then continuing for an average of 20 weeks before plateauing. Weight regain varied with follow-up, with study participants experiencing significant periods of weight regain at eight, 12, and 20 weeks after AOM discontinuation. The amount of weight regained depended on several factors, including the type of medication taken by participants and the consistency of their lifestyle change. For example, participants who completed a 36-week treatment of tirzepatide, a commercially available GLP-1 RA, regained almost half the weight previously lost after switching to a placebo.
The authors note the meta-analysis did not include studies of lifestyle interventions and bariatric surgery, reducing the degree to which different weight loss approaches could be compared within the context of the study. They also note that weight regain has been reported with other weight loss methods, such as gastric bypass and vertical banded gastroplasty.
END
Health: Anti-obesity medications associated with weight rebound post-treatment
2025-07-22
ELSE PRESS RELEASES FROM THIS DATE:
“Forever chemicals” linked to higher risk of type 2 diabetes
2025-07-21
New York, NY (July 21, 2025) — Exposure to a class of synthetic chemicals known as per- and polyfluoroalkyl substances (PFAS)—often called “forever chemicals”—may increase the risk of developing type 2 diabetes, according to a new study led by Mount Sinai researchers. The findings were published today in eBioMedicine.
The team conducted a nested case-control study (an observational study that is conducted within a larger cohort study) within BioMe, a large, electronic health record-linked research database comprising ...
Near tripling in US reported lidocaine local anesthetic poisonings/deaths over past decade
2025-07-21
Poisonings and deaths linked to the use of the local anaesthetic lidocaine have nearly tripled in the US over the past decade, finds an analysis of National Poison Data System (NPDS) reports, published online in the journal Regional Anesthesia & Pain Medicine
This increase contrasts with the overall fall in reported poisonings and deaths from other types of local anaesthetics over the same period, the analysis shows.
Local anaesthetics are widely used for pain control, but carry an inherent risk of systemic toxicity, referred to as LAST, prompting multiple professional societies to issue ...
Despite self-perceived sensitivities, study finds gluten and wheat safe for many people with IBS
2025-07-21
A new study from McMaster University researchers has found that many people with irritable bowel syndrome (IBS) who believe they are sensitive to gluten or wheat may not actually react to these ingredients.
IBS is an intestinal disorder that affects an estimated 10 per cent of Canadians – one of the highest prevalence rates globally, according to the Canadian Digestive Health Foundation. It can be disruptive and debilitating, and its underlying cause is unclear.
The study, published in The Lancet Gastroenetrology ...
New subtype of diabetes identified in Africa in first largescale study
2025-07-21
A new subtype of diabetes has been identified in children and young people in sub-Saharan Africa and could mean many patients are not on the best treatment for them.
The new finding, published in The Lancet Diabetes & Endocrinology and funded by the UK’s National Institute for Health and Care Research (NIHR), challenges the global understanding of diabetes in young people. It raises concerns that many patients across the continent, and possibly beyond, may need their diagnosis updated to access the best treatment.
The discovery was made through the largest study of its kind in the region. Researchers found that nearly two thirds (65 per cent) of young ...
A new diabetes subtype identified in Sub-Saharan Africa and Black Americans, study finds
2025-07-21
An international team of researchers has made a key discovery: many children and young adults in Sub-Saharan Africa diagnosed with type 1 diabetes (T1D) may have a different form of the disease - one not caused by the immune system, unlike classic T1D. This discovery could change how diabetes is diagnosed, treated and managed across the region, paving the way for more accurate care and better outcomes.
The research was published today in Lancet Diabetes and Endocrinology.
“This is the first study across several Sub-Saharan African countries to use the same lab tests and genetic tools to learn more about type 1 diabetes. We've done similar research in the U.S. with different groups, ...
A simple filter for rare earth elements will ensure a clean domestic supply of these crucial metals
2025-07-21
(Santa Barbara, Calif.) — Rare earth elements sustain the Information Age, and securing a supply of these metals has become a matter of national and economic security. They’re ubiquitous in our smart technologies, high performance materials and industrial catalysts. Yet reclaiming them is complex, dangerous and expensive.
That’s why UC Santa Barbara’s Justin Wilson has partnered with the mineral recovery company REEGen. “We’ve developed a new approach to extract rare earth elements from end-of-life products like electronic waste from phones, batteries and discarded catalytic converters,” said Wilson, a professor in UCSB’s Department ...
UCF researchers developing new methods to passively mitigate lunar dust for space exploration
2025-07-21
Lunar dust is more than a mild irritant or hallmark of an untidy room like dust found on Earth.
Lunar dust particles are sharp and abrasive due to the lack of atmosphere gradually dulling their surfaces, leading them to potentially damaging critical lunar equipment or causing respiratory issues for astronauts. Managing lunar dust (also known as regolith) and safeguarding astronauts or sensitive equipment on the moon isn’t as simple as sweeping it up with a broom and pan.
That’s why a team of NASA-funded UCF researchers is pioneering a new nanocoating to passively mitigate the effects of lunar dust, ...
Discovering new materials: AI can simulate billions of atoms simultaneously
2025-07-21
Imagine the concrete in our homes and bridges not only withstanding the ravages of time and natural disasters like the intense heat of wildfires, but actively self-healing or capturing carbon dioxide from the atmosphere.
Now, researchers at the USC Viterbi School of Engineering have developed a revolutionary AI model that can simulate the behavior of billions of atoms simultaneously, opening new possibilities for materials design and discovery at unprecedented scales.
The current state of the world’s climate is a dire one. Brutal droughts, evaporating glaciers, ...
University Hospitals Seidman Cancer Center becomes first in the United States to implement Akesis Inc. innovative Galaxy RTI device for patient treatment
2025-07-21
CLEVELAND, Ohio – Akesis, Inc. (Akesis), a leader in cutting-edge radiation oncology technology, has formed a groundbreaking collaboration with University Hospitals Seidman Cancer Center, a nationally recognized cancer care institution. Through this alliance, UH Seidman Cancer Center becomes the first medical center in the United States to implement the innovative Akesis Galaxy RTi device for patient treatments, while also serving as the flagship site for research and clinical demonstration of this advanced technology.
As part of the agreement, UH Seidman Cancer Center will incorporate the Galaxy RTi into the stereotactic radiosurgery (SRS) program, aiming to set new benchmarks ...
FAMU-FSU research identifies U.S. dams at greatest risk of overtopping
2025-07-21
The number of dams in the United States at risk of overtopping is increasing, threatening their structural integrity and downstream communities, according to new research from the FAMU-FSU College of Engineering.
The study, published in Nature Communications, examined data from 33 dams over 50 years to determine how overtopping probability changed since 1973. The research found an increasing trend in the number of dams exhibiting critical overtopping probabilities (low, moderate and high) and ...